SPONSOR
Canadian Cancer Trials Group
Total Trials
4
Recruiting
4
Phases
Phase 2, Phase 3
Conditions studied: Hepatocellular CarcinomaUnresectable/Metastatic MelanomaColorectal CancerProstate Cancer (Adenocarcinoma)
NCT06880523 Phase 2
Recruiting
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
NCT02821013 Phase 3
Recruiting
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Unresectable/Metastatic Melanoma
NCT07152821 Phase 3
Recruiting
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Colorectal Cancer
NCT06592924 Phase 3
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Prostate Cancer (Adenocarcinoma)